id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S3446 R6435 |
Andersen (control unexposed, disease free), 2019 | Carbimazole embryopathy (aplasia cutis, esophageal atresia, choanal atresia, and omphalocele) | early pregnancy | population based cohort retrospective | unexposed, disease free | Adjustment: Yes | 20.00 [12.00;34.00] | -/1,574 -/1,159,181 | - | 1,574 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3364 R6138 |
Seo (control exposed to PTU), 2018 | MMI embryopathy (at least 1 of the following diagnoses: choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomaly, or aplasia cutis) | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
5.95 [2.43;14.58] C excluded (control group) |
8/1,120 12/9,930 | 20 | 1,120 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3365 R6150 |
Seo (control unexposed, NOS), 2018 | MMI embryopathy (at least 1 of the following diagnoses: choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomaly, or aplasia cutis) | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 9.27 [4.62;18.63] | 8/1,120 2,019/2,872,109 | 2,027 | 1,120 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3353 R8732 |
Yoshihara (control exposed to PTU), 2012 | MMI/CMZ embryopathy (at least 1 of following malfo: choanal atresia, esophageal atresia, omphalocele or aplasia cutis) | 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
33.34 [1.99;559.48] C excluded (control group) |
14/1,231 0/1,399 | 14 | 1,231 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3350 R8733 |
Yoshihara (control unexposed, sick), 2012 | MMI/CMZ embryopathy (at least 1 of following malfo: choanal atresia, esophageal atresia, omphalocele or aplasia cutis) | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 45.42 [2.71;762.21] C | 14/1,231 0/1,906 | 14 | 1,231 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3379 R8736 |
Clementi, 2010 | Choanal atresia or omphalocele (as a part of Carbimazole embryopathy) | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No | 11.85 [6.16;22.81] C | 10/160 202/36,102 | 212 | 160 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3357 R8724 |
Barbero, 2008 | Choanal atresia (as a part of Carbimazole embryopathy) | 1st trimester | case control | unexposed, disease free | Adjustment: No | 17.75 [3.49;121.40] | 10/12 51/232 | 61 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3396 R6344 |
Di Gianantonio, 2001 | MMI embryopathy (i.e., choanal atresia or esophageal atresia) | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 27.01 [1.29;564.73] C | 2/204 0/1,089 | 2 | 204 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 14.62 [10.40;20.55] | 2,316 | 4,301 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: control unexposed, disease free; 2: control unexposed, NOS; 3: control unexposed, sick;
Asymetry test p-value = 0.6287 (by Egger's regression)
slope=2.5350 (0.3307); intercept=0.4064 (0.7772); t=0.5228; p=0.6287
excluded 3353, 3364